Epistem in fibrosis research deal with GlaxoSmithKline
UK biotech and personalized medicines company Epistem (LSE:EHP) has entered into a three year biomarker collaboration with pharma giant GlaxoSmithKline (LSE: GSK) in the field of fibrosis research.
The collaboration will focus on identifying key characteristics of diseased fibrotic tissue on which Epistem will apply its proprietary RNA-Amp technology to facilitate building an in depth understanding of the disease. Financial terms of the accord were not disclosed.
RNA-AmpTM is highly sensitive amplification technology which is able to provide gene expression information from small-tissue samples and low of numbers of cells, eg, those obtained from the bulb of cells at the base of a single hair follicle, as well as laser captured microdissected (LCM) samples. Epistem says it is now the preferred partner of choice for a range of pharmaceutical companies providing gene expression biomarker information to support drug development programs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze